Green Fresh Biotechnology Company (1084) Fair Value & Analysis
Consumer Defensive · HK · Market cap HK$573M
Fair value as of: Aug 13, 2026
From 13 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$0.1900 to HK$0.3800 (+100.0%) since Aug 5, 2026. Share price +1.4% over the past month.
Below-average quality, and screening another 46% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.4600). The favourable scenario is already priced in.
- Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (HK$0.2200 to HK$0.4600) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.5801 – HK$4.34 · fair‑value band HK$0.2200 – HK$0.4600 · the HK$0.7000 price screens above the HK$0.3800 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Green Fresh Biotechnology Company (1084) currently trades at HK$0.7000, while our model-based Fair Value estimate is HK$0.3800, implying the stock looks roughly 45.7% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Green Fresh Biotechnology Company generated revenue of HK$905M at a net margin of 0.7%. Revenue declined 6.7% year over year. It earns a return on equity of 0.6%. Net debt stands at HK$485M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.2200 (bear case) to HK$0.4600 (bull case); at HK$0.7000, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 97% fair-value upside, at -46%, 1084 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (HK$0.6500) versus Earnings-Based (HK$0.0600). Highest evidence: Residual Income (76).
Notify me when 1084 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Green Fresh Biotechnology Company Limited, an investment holding company, engages in the production of seaweed-based and plant-based hydrocolloid products in the Mainland China, Europe, rest of Asia, South America, North America, Africa, and Oceania.
Full company description
Green Fresh Biotechnology Company Limited, an investment holding company, engages in the production of seaweed-based and plant-based hydrocolloid products in the Mainland China, Europe, rest of Asia, South America, North America, Africa, and Oceania. The company operates through five segments: Manufacturing and Sales of Agar-Agar; Manufacturing and Sales of Carrageenan; Manufacturing and Sales of Konjac Products; Manufacturing and Sales of Blended Products; and Others. It offers carrageenan, agar agar, konjac gum, and flour products, as well as blended products; and solutions, including soft candy, jelly/pudding, meat product, plant-based meat product, and other applications. The company was formerly known as Green Future Food Hydrocolloid Marine Science Company Limited and changed its name to Green Fresh Biotechnology Company Limited in July 2025. Green Fresh Biotechnology Company Limited was founded in 2001 and is headquartered in North Point, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Green Fresh Biotechnology Company reported revenue of HK$904M in FY2025 versus HK$1.2B in FY2021, a compound −6.1%/yr. Reported net income was HK$6.6M in FY2025, compounding −49.8%/yr from FY2021.
of which total revenue +7.2 pp · buybacks/dilution −0.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
1084 screens 46% overvalued. Compare with Muyuan Foods Group →
Peer Group
Farm Products · 298 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Farm Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Muyuan Foods Group 002714 | ¥40.15 | ¥47.42 | +18% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,150 IDR | 6,818 IDR | +116% |
| Charoen Pokphand Foods Public Company CPF | 21.90 THB | 43.24 THB | +97% |
| PT Triputra Agro Persada Tbk TAPG | 1,805 IDR | 3,087 IDR | +71% |
| PT FAP Agri Tbk FAPA | 7,350 IDR | 6,420 IDR | -13% |
| PT Japfa Comfeed Indonesia Tbk JPFA | 2,260 IDR | 6,974 IDR | +209% |
| PT Jhonlin Agro Raya Tbk JARR | 1,890 IDR | 610.80 IDR | -68% |
| PT Nusantara Sawit Sejahtera Tbk NSSS | 860.00 IDR | 402.24 IDR | -53% |
| PT Sinar Mas Agro Resources and Technology Tbk SMAR | 5,625 IDR | 16,227 IDR | +188% |
| PT Dharma Satya Nusantara Tbk DSNG | 1,320 IDR | 2,696 IDR | +104% |
Compare Green Fresh Biotechnology Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Green Fresh Biotechnology Company (1084) overvalued or undervalued?
What is the fair value of 1084?
What is the quality score of 1084?
What is the revenue of Green Fresh Biotechnology Company (1084)?
What is the net profit margin of 1084?
Does Green Fresh Biotechnology Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Green Fresh Biotechnology Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.